This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Nplate
  • /
  • Safety and Efficacy Study of Romiplostim to Treat ...
Clinical trial

Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Read time: 1 mins
Last updated:29th Sep 2011

The purpose of this study is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric subjects with Immune Thrombocytopenia Purpura (ITP) as measured by durable platelet response.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
Enrollment: 62
Study Start Date: December 2011
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)

- Experimental:
- Placebo Comparator: Placebo

Related journal: Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.

Category Value
Study start date 2011-09-29

View full details